-+ 0.00%
-+ 0.00%
-+ 0.00%

BioPorto Activates First US Trial Site for Urine Test in Adult Patients with Acute Kidney Injury

MT Newswires·08/18/2026 09:54:56
Listen to the news
09:54 AM EDT, 08/18/2026 (MT Newswires) -- BioPorto (BIOPOR.CO) said Tuesday it activated its first US clinical site for a validation study evaluating its ProNephro AKI urine test in adult patients with acute kidney injury. The in vitro diagnostics company's ProNephro AKI US Adult Urine NGAL validation study aims to validate ProNephro AKI's clinical performance in assessing the risk of moderate to severe acute kidney injury among adult patients admitted to the intensive care unit.